https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
Durvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. Patients with unresectable stage III non-small-cell lung cancer, Eastern Cooperative Oncology Group performance status
Like
Comment
Share
